Medtronic Tops Charts With InSync FDA Approval Ahead Of Schedule
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will be allowed to use patients enrolled in the trials of its next-generation InSync III to partially fulfill a 1,000-patient, post-approval study requirement for the current generation InSync biventricular pacing system for congestive heart failure, FDA says.